SN BioScience Initiates Global Phase 1b/2 Trial of SNB-101 for Small Cell Lung Cancer with Zero High-Grade Diarrhea Events
Key Insights
SN BioScience (search) has dosed the first patient in a global Phase 1b/2 trial of SNB-101, a nanoparticle formulation of SN-38, enrolling up to 135 patients with extensive-stage small cell lung cancer.
Korean Phase 1 data showed zero Grade 3 or higher diarrhea events, an 83.3% disease control rate in high-dose cohorts, and a mean progression-free survival of 6.3 months.
The drug has received FDA Fast Track designation and orphan drug status from both FDA and EMA, establishing regulatory pathways for potential accelerated approval.
SN BioScience (search) has initiated dosing of the first patient in a global Phase 1b/2 clinical trial evaluating SNB-101, a nanoparticle formulation of SN-38, in patients with extensive-stage small cell lung cancer (ES-SCLC). The multi-center trial will enroll up to 135 patients across sites in the United States, Europe, and other global locations.
The advancement to international testing is anchored by a remarkable safety signal from Korean Phase 1 data: zero Grade 3 or higher diarrhea events, addressing the notorious gastrointestinal tolerability issues associated with irinotecan, the parent compound of SN-38. This tolerability profile represents a potentially significant differentiation from existing SN-38 delivery methods.
Trial Design and Regulatory Framework
The study employs a sequential three-stage architecture designed to optimize dosing before expansion. The Phase 1b dose-escalation phase uses a 3+3 design to establish the maximum tolerated dose across 50–70 mg/m² dose levels. This will be followed by Phase 2a dose optimization to identify the optimal therapeutic dose, then Phase 2b expansion at the optimized dose to evaluate clinical activity across a broader patient population.
SNB-101 has secured a comprehensive regulatory framework with FDA Fast Track designation for SCLC, along with orphan drug designations from both the FDA and European Medicines Agency (EMA). These designations establish pathways for potential accelerated approval if efficacy data support regulatory submission.
Efficacy Signals from Korean Phase 1
The Korean Phase 1 cohort demonstrated an 83.3% disease control rate in high-dose cohorts and a mean progression-free survival of 6.3 months in SCLC patients. These outcomes compare favorably with currently available later-line treatment options, including Zepzelca® (lurbinectedin) and topotecan, where median PFS typically sits below four months in later-line settings.
Key efficacy endpoints for the Phase 2 portion include objective response rate (ORR), progression-free survival (PFS), and overall survival (OS), which will generate clinical evidence necessary to support the regulatory review process.
Combination Strategy Development
SN BioScience (search) is pursuing parallel development tracks with combination therapies alongside the monotherapy program. The company has obtained EMA approval for a clinical study evaluating SNB-101 in combination with one immunotherapy agent and plans to submit an additional Clinical Trial Application (CTA) within this year for a separate immunotherapy combination study.
The combination strategy targets immunotherapy agents including anti-PD-1 (search), anti-PD-L1 (search), and DLL3 (search)-targeted BiTE® T-cell engager therapies currently used in standard SCLC treatment. In the context of small cell lung cancer, where tarlatamab's DLL3-targeting mechanism has reset expectations for later-line response, a tolerable SN-38 backbone could serve as a rational combination partner.
Clinical Significance and Market Context
The development addresses an important unmet need in SCLC, particularly in later-line settings where both tolerability and efficacy remain challenging. SN BioScience (search) is also pursuing expansion of SNB-101 into additional solid tumor indications, including gastric and pancreatic cancers, through ongoing collaborations and strategic discussions with global pharmaceutical companies.
The critical marker for the program's success will be whether the zero Grade 3 or higher gastrointestinal toxicity profile observed in Korean patients holds across international sites during dose escalation. If this tolerability advantage proves consistent globally, SNB-101's differentiation from conventional irinotecan formulations could establish a new therapeutic option for SCLC patients who have exhausted standard treatment options.